Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients

Inclusion Criteria:

• Adults < 60 years old
• Diagnosis of HS according to European Dermatology guidelines:
• Recurrent inflammation occurring more than 2 times in the past 6 months in theinverse regions of the body, presenting with nodules, sinus-tracts and/orscarring.
• Signs: Involvement of axilla, genitofemoral area, perineum, gluteal area (andinfra-mammary areafor women). Presence of nodules (inflamed or noninflamed),sinus tracts (inflamed or noninflamed), abscesses, scarring (atrophic, mesh-like,red, hypertrophic or linear)
• Active HS with i) ≥ 1 year of evolution and ii) ≥ 4 flares during the previous year
• Clinical severity of HS at inclusion: Hurley stage 2
• BMI < 35
• Written informed consent from patient
• Patient able to complete DLQI
• Patients affiliated to the French health system (Assurance Maladie), except Frenchstate medical aid beneficiaries (Aide Médicale d'Etat)
• Active compatible contraception for men and women of childbearing or inability toprocreate
• Available laboratory blood test performed within the last 2-months Non inclusion Criteria:
• Person < 18 and ≥ 60 years old
• Former stage 3 HS
• Previous use of the experimental treatment
• Unauthorized drugs for the study during the month preceding the inclusion
• Any contra-indication to study treatments or excipient (e.g. lactose, cornstarch,riboflavin notably): pregnancy, breastfeeding, known allergy to experimental or reference drugs, wheat allergy,tendinopathy, QT prolongation, bradycardia, heart failure, heart rhythm disturbances,hydroelectrolytic disorders, hypokalemia, coagulation disorders, severe liver/kidneydysfunction, porphyria, mandatory use of nonsteroidal anti-inflammatory drugs (NSAIDs) forother medical conditions
• Unbalanced diabetes (ie HbA1c above 7%)
• Dysphagia, untreated gastro-oesophageal reflux/ulcer
• BMI ≥ 35
• Immune suppression, inflammatory disease, including gastroenterologic andrheumatologic inflammatory conditions
• Lactase deficiency, lactose and galactose intolerance
• Malabsorption syndrome
• Person living in the same household as another patient
• Person under guardianship or curatorship
• Individuals with any condition which, in the opinion of the investigator, mightinterfere with the evaluation of the study objectives (e.g patient unable to completeDLQI, or poor predictable observance
• Participation in another interventional research on health products studies
• Patients requiring repeated (more than 3/year) use of antibiotics for a chronicdisease other than HS
• Alcohol-dependant patients defined as an addiction to alcohol with a negative impacton health, social or personal life

Exclusion criteria: Pregnancy QT prolongation Abnormal result of routine lab tests corresponding tocontra-indication to study treatments Unauthorized drug for the study during all the study (from study treatments interactions listed in the SmPC, Cf. unauthorized drug listed innon-inclusion criteria). Development of hypersensitivity to any of the study products and/or excipients (e.g.lactose, corn starch, riboflavin).